Cargando…
Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas
Advanced pancreatic ductal adenocarcinoma (PDAC) and hepatocellular carcinoma (HCC) are non-curable diseases with a particularly poor prognosis. Over the last decade, research has increasingly focused on the microenvironment surrounding cancer cells, and its role in tumour development and progressio...
Autores principales: | Neuzillet, Cindy, de Gramont, Armand, Tijeras-Raballand, Annemilaï, de Mestier, Louis, Cros, Jérome, Faivre, Sandrine, Raymond, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960190/ https://www.ncbi.nlm.nih.gov/pubmed/24393789 |
Ejemplares similares
-
Targeting cancer cell metabolism in pancreatic adenocarcinoma
por: Cohen, Romain, et al.
Publicado: (2015) -
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients
por: Serova, Maria, et al.
Publicado: (2015) -
Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?
por: Boilève, Alice, et al.
Publicado: (2021) -
Pancreatic cancer orthotopic graft in a murine model
por: Muzzolini, Milena, et al.
Publicado: (2023) -
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
por: Serova, Maria, et al.
Publicado: (2016)